Results 31 to 40 of about 45,933 (222)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer

Frontiers in Pharmacology, 2022
Background: Everolimus is one of the key drugs for the treatment of advanced breast cancer. The optimal target concentration range for everolimus therapy in patients with breast cancer has not yet been established.
Masaki Hirabatake, Tomoyuki Mizuno, Tomoyuki Mizuno, Hironori Kato, Tohru Hashida   +4 more
doaj   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations

Contemporary Clinical Trials Communications, 2021
This randomized, double-blind controlled trial of everolimus in individuals with germline phosphatase and tensin homolog mutations (PTEN) was designed to evaluate the safety of everolimus compared with placebo and to evaluate the efficacy of everolimus ...
Antonio Y. Hardan, Booil Jo, Thomas W. Frazier, Patricia Klaas, Robyn M. Busch, Kira A. Dies, Rajna Filip-Dhima, Anne V. Snow, Charis Eng, Rabi Hanna, Bo Zhang, Mustafa Sahin   +11 more
doaj   +1 more source

Comprehensive In Vitro Profiling Demonstrates Successful Immune Evasion of Bioengineered Immune‐Shielded Heart Valves

Advanced Healthcare Materials, EarlyView.
Living donor heart valves offer superior durability for pediatric patients but trigger immune rejection. Lentiviral delivery of viral immune‐evasion genes US2 and Serpin b9 into donor valve cells and valve tissue suppresses HLA expression, reduces PBMC clustering and cytotoxic killing, and induces transcriptional immune‐tolerance programs, paving the ...
Abraham van Wijk, Leanne Van den Berg, Isa B. M. Velraeds, Valentina Osorio Zuluaga, Emma T. M. Peereboom, Martijn J. W. E. Rabelink, Arnaud Zaldumbide, Rob C. Hoeben, Marie‐Jose T. H. Goumans, Eric Spierings, Carlijn V. C. Bouten, Marijn C. Peters   +11 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

, 2017
Objective: This phase II trial investigates the efficacy and safety of low-dose everolimus in combination with cisplatin-fluorouracil chemotherapy in patients with advanced gastric cancer.
Shen, Ying-Chun;Li, Chung-Pin;Yen, Chia-Jui;Hsu, Chiun;Lin, Yu-Lin;Lin, Zhong-Zhe;Chen, Li-Tzong;Su, Wu-Chou;Chao, Yee;Yeh, Kun-Huei;Cheng, Ann-Lii, 林宗哲;林育麟;鄭安理;許駿;葉坤輝   +1 more
core   +1 more source

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

BMC Cancer, 2017
Background Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as
Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries, Steven de Jong   +3 more
doaj   +1 more source

Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex‐specific body weight loss in humans

Journal of Cachexia, Sarcopenia and Muscle, 2023
Background Previous data from a 2‐year randomized controlled trial (CRAD001ADE12) indicated that mammalian target of rapamycin (mTOR) inhibition by everolimus slowed cyst growth in patients with autosomal‐dominant polycystic kidney disease (ADPKD ...
Marwan Mannaa, Pia Pfennigwerth, Jens Fielitz, Maik Gollasch, Michael Boschmann   +4 more
doaj   +1 more source

The Synergistic Effect of Tacrolimus (FK506) or Everolimus and Azoles Against Scedosporium and Lomentospora Species In Vivo and In Vitro

Frontiers in Cellular and Infection Microbiology, 2022
Scedosporium and Lomentospora infections in humans are generally chronic and stubborn. The use of azoles alone cannot usually inhibit the growth of these fungi.
Zikuo Wang, Mei Liu, Luyao Liu, Linyun Li, Lihua Tan, Yi Sun   +5 more
doaj   +1 more source